Teva Pharmaceuticals
TEVA
455 hedge funds and large institutions have $7.14B invested in Teva Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 132 increasing their positions, 146 reducing their positions, and 58 closing their positions.
43% more capital invested
Capital invested by funds: $4.98B → $7.14B (+$2.16B)
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
2.18% more ownership
Funds ownership: 50.76% → 52.94% (+2.2%)
1% less funds holding
Funds holding: 459 → 455 (-4)
2% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 58
4% less call options, than puts
Call options by funds: $324M | Put options by funds: $338M
10% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 146
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$117M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$79.4M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$74.9M |
| 4 |
IAM
Ion Asset Management
Herzliya,
Israel
|
+$58.5M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$35.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$75.3M |
| 2 |
Jane Street
New York
|
-$61.8M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$16.6M |
| 4 |
HM
HealthCor Management
New York
|
-$13.4M |
| 5 |
Millennium Management
New York
|
-$12.4M |
TEVA Hedge Fund Activity: Q2 2020 in Review
455 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2020, worth a combined $7.14B — up 43% from $4.98B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of TEVA and 57 opened new positions — a net loss of 1 holder — while 146 trimmed existing stakes and 132 added.
The largest buyer was Capital World Investors, adding an estimated $117M. The largest seller was Norges Bank, cutting an estimated $75.3M.
- 455 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2020, down from 459 in Q1 2020.
- Funds reported $7.14B of Teva Pharmaceuticals stock for Q2 2020, up 43% quarter-over-quarter.
- 57 funds opened new Teva Pharmaceuticals positions in Q2 2020 and 58 closed out, a net change of -1 holder.
- The largest Teva Pharmaceuticals buyer in Q2 2020 was Capital World Investors, an estimated $117M added.
- The largest Teva Pharmaceuticals seller in Q2 2020 was Norges Bank, an estimated $75.3M sold.
Based on aggregated 13F filings for Q2 2020.